Ferritin Testing Market By Type (Reagents & assay kits, Instruments, Consumables, Software & middleware, Services), By Sample Type (Serum, Plasma, Whole blood, Dried blood spot), By Technology (Chemiluminescent immunoassay, Enzyme-linked immunoassay, Immunoturbidimetry, Nephelometry, Immunofluorescence assay, Lateral flow rapid tests, Others), By Analyte Scope (Single-analyte ferritin, Iron studies panel, Inflammation-adjusted panels, Extended anemia workup bundles), and By End User (Hospital laboratories, Independent laboratories, Diagnostic centers labs, Physician office labs (POLs) & clinics, Dialysis centers, Oncology centers, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Ferritin Testing Market in the coming years?

The Ferritin Testing Market accounted for USD 1.18 Billion in 2024 and USD 1.26 Billion in 2025 is expected to reach USD 2.49 Billion by 2035, growing at a CAGR of around 7.02% between 2025 and 2035. The Ferritin Testing Market is engaged in the design, manufacturing, and marketing of diagnostic tests designed to determine the amount of ferritin in the blood. The iron-carrying protein ferritin is usually measured to diagnose iron deficiency anaemia, haemochromatosis, and chronic diseases. The market comprises hospitals, diagnostic laboratories, and research centres that use ferritin tests in treating patients and also in research. This market is growing due to the rising incidences of iron-related disorders, the increased consciousness of the need to detect diseases at an early stage, and the development of diagnostic technology. It also contains a range of different test formats, including ELISA, immunoassays, and rapid test kits.

What do industry experts say about the Ferritin Testing market trends?

“Ferritin testing is a crucial diagnostic tool for evaluating iron stores and identifying iron deficiency anemia, which remains one of the most common nutritional deficiencies worldwide.”

• Dr. Robert T. Means Jr., MD (Professor of Medicine, Hematology, University of Kentucky College of Medicine)

“Serum ferritin remains the most reliable marker for assessing total body iron, but clinicians should interpret results carefully, especially in the presence of inflammation or chronic disease, as ferritin is an acute-phase reactant.”

• Dr. Michael Auerbach, MD (Clinical Professor of Medicine, Georgetown University School of Medicine)

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Ferritin Testing market?

How does anemia, screening, population, growth, awareness, healthcare, advancement, education, urbanization, diagnostics boost market?

The overall incidence of anaemia, especially iron-deficiency anaemia, is so widespread globally that the need to test ferritin becomes a major factor in ferritin testing demand. The World Health Organisation (WHO) describes anaemia as a known condition affecting close to 30% of the entire world population, and women and children are the most susceptible. India, with 52.9% of women of reproductive age having anaemia according to the NFHS-5 report, indicates a dire need to establish accurate diagnostic measures like ferritin assays. With population increase and urbanisation, medical facilities are being developed to enhance access to routine screening programmes.

Governments across the world have initiated efforts, such as the Anaemia Mukt Bharat programme in India, to enhance screening and treatment of anaemia, with an aim of raising awareness. The increased speed and accuracy of ferritin measurement, as a result of advances in diagnostic technology, such as point-of-care testing, have facilitated its increased use. Health ministries and NGOs also conduct educational campaigns that encourage the early diagnosis of iron deficiency, a phenomenon that is driving the expansion of the ferritin testing market around the world.

Can technology, integration, automation, accuracy, reliability, results, speed, efficiency, labs, clinics drive demand?

The increased need to conduct ferritin tests is facilitated by the increasing advancement in technology and automation, which facilitates quicker, more precise, and accurate findings. In India, the National Family Health Survey (NFHS-5) notes that more than half of women and children have been identified to be affected by anaemia, and this necessitates a more accurate determination of their iron status. The clinical laboratory automation and integration lower the manual error and turnaround time in order to diagnose and provide treatment in time. With clinics embracing point-of-care devices, rapid results are offered beyond conventional labs, increasing access in resource-constrained locations.

Research in journals such as the Journal of Clinical Biochemistry and Nutrition demonstrates that these devices have sensitivity and specificity rates in the 90% range. Data management and public health activities, including the anaemia reduction programmes of the WHO, are also supported by electronic health records. A combination of these factors contributes to the increasing demand for ferritin testing as a powerful and effective diagnostic tool.

Are concerns over standardization, calibration, interpretation, consistency, errors, outcomes, quality, protocols, validation, safety holding back?

Issues of standardisation, calibration, interpretation, and regularity are major problems that are affecting the expansion of the ferritin testing market. The National Institutes of Health (NIH) noted that results obtained in different laboratories may vary widely, which can influence clinical decisions when ferritin is used to assess iron status.

Research papers written by the Centres for Disease Control and Prevention (CDC) point out that differences in calibration standards lead to differences in ferritin levels across various platforms and that the coefficient of variation of the measurements is sometimes higher than 15%. Moreover, recent studies conducted in major universities reveal that the absence of standard testing procedures is a source of interpretation errors that can lead to incorrect diagnosis of iron deficiency or overload.

The World Health Organisation (WHO) confirms that test reliability is being enhanced by validated, harmonised reference materials that will be used to enhance test reliability across the globe. Lack of better quality standards, better protocols, and better validation standards makes ferritin testing results unpredictable, undermining clinical confidence and market growth.

Will innovation, wearables, home-testing, AI, data, cloud, integration, apps, personalization, monitoring open doors?

The ferritin testing market will change with innovation in wearables, home testing, AI, cloud integration, and personalised health apps, which bring iron level control closer and more proactive. Tests of iron storage (ferritin tests) are essential to diagnosing iron overload and anaemia. The World Health Organisation states that iron deficiency anaemia occurs in approximately 30% of the global population, including women and children, which means that easy-to-conduct testing methods are necessary. The development of home-testing devices that do not require attending a clinic and are connected to smartphones and cloud platforms makes it possible to regulate ferritin levels early on and in a more effective way.

Analytics with AI enhances the interpretation of results, especially when there is inflammation that interferes with the ferritin levels. Wearables and app integration facilitate continuous monitoring, customising care, and initiating consultations at the right time. Such technologies are in line with national initiatives such as the anaemia surveillance programmes by the U.S. CDC and present a pathway to broader access to ferritin testing and better management of iron deficiency across the world.

Does expansion into emerging, economies, investment, infrastructure, collaboration, manufacturing, distribution, scale, markets, growth offer potential?

Gaining access to emerging economies presents tremendous opportunities to the ferritin testing market with increasing healthcare expenditure, better infrastructure development, and increased interest in learning about nutritional deficiencies. Indeed, this has been the case in India, where National Family Health Survey (NFHS-5) statistics show that more than 57% of women between the ages of 15 and 49 years and almost 67% of children below the age of five years are anaemic, a condition usually associated with iron deficiency, which makes the testing of ferritin more in demand.

In these areas, governments are improving co-operation between the state and non-state healthcare systems to increase diagnostic capacities. The use of India’s Ayushman Bharat programme and investments in manufacturing and distribution networks have increased the number of people who can now access healthcare services in rural and semi-urban locations. All these factors suggest that ferritin testing has a high growth potential when it comes to providing solutions to iron-related health problems in developing economies.

What are the key market segments in the Ferritin Testing industry?

Based on the type, the Ferritin Testing Market is classified into Reagents & assay kits, Instruments, Consumables, Software & middleware, and Services. Reagents and assay kits are the most noticeable market segment in the ferritin testing market. The reason behind this dominance is that ferritin assays are done at a very high rate in clinical laboratories and hospitals, and the tests need a continuous supply of reagents and assay kits. These kits play a vital role in the correct quantification of ferritin levels, which is important in the diagnosis of iron-related disorders. There has also been an increased pressure on high-quality, dependable assay kits due to improvements in immunoassay technologies and an increasing use of automated testing systems. Their repetitive application, as opposed to infrequent investments in instruments, also helps them to gain prominence in the market.

Based on the Sample Type, the Ferritin Testing Market is classified into Serum, Plasma, Whole blood, Dried blood spot. The serum segment is the largest in the ferritin testing market. Serum is commonly popular because it is stable and has high precision when measuring ferritin, and it is therefore the gold standard sample type in clinical diagnosis. It offers a transparent medium without any interference, which is essential in immunoassays for the detection of ferritin. The majority of automated analysers and standardised analysis procedures are biased towards serum samples, once again supporting its pre-eminence. Its daily application in hospitals and diagnostic laboratories contributes to the dominance of the segment in the market.

Which regions are leading the Ferritin Testing market, and why?

The North American ferritin testing market is a dominant player because of the developed healthcare system, extensive knowledge on preventative health screening, and the high prevalence rates of iron-related diseases like anaemia and haemochromatosis. The existence of large diagnostic companies and research centres provokes the active development of innovations and access to high-precision testing solutions. Insurance coverage provided on routine blood tests by the government is also contributing to the rise of this market. Ageing and increasing the focus on early disease diagnosis are other factors driving the increased demand for ferritin testing.

The high expenditure on healthcare per capita and the effective regulatory frameworks in the region also serve to guarantee the test accuracy and reliability. All these together have established North America as a leading force in the ferritin testing market worldwide. The presence of new technologies adapted to AI, like diagnostic equipment, increases the effectiveness of testing. The high availability of trained medical practitioners also enhances the faster implementation of ferritin testing in the region.

A combination of factors is causing the Asia Pacific ferritin testing market to be a leader. The high rates of population growth (China and India in particular) are the causes of the increased rates of iron deficiency anaemia and other associated disorders, resulting in the need to test ferritin. There is also an increase in awareness of nutritional health and increased healthcare infrastructure that is enhancing diagnostic services.

Increased adoption rates of ferritin testing are also driven by the increasing number of middle-income people living in the region, as well as the rising access to advanced medical technologies. Further, its growth is being strengthened by government programmes in maternal and child health, coupled with the growth in investment in healthcare diagnostics. The combination of the demographic, economic, and healthcare development variables makes the Asia Pacific a force to reckon with in the world ferritin testing market.

What does the competitive landscape of the Ferritin Testing market look like?

The ferritin testing market is a competitive market with well-established diagnostics companies like Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, and bioMérieux leading the market. These players are building the industry with advances such as immunoassay automation, incorporating point-of-care (POC)-based solutions, and expanding into untapped markets.

As an example, Abbott has deployed high-throughput ferritin systems to increase testing throughput, and Siemens Healthineers has expanded its assay offerings to provide a quicker turnaround in hospital platforms, both efforts that strengthen their leadership in the market. Further, Roche and Thermo Fisher are optimising reagent systems optimally suited to automated laboratory processes.

BioMérieux's (POC front) acquisition of SpinChip Diagnostics is a case in point of strategising to quickly get to the bedside for a ferritin test. Generally, the competition prioritises balancing throughput, accuracy, and accessibility to meet global diagnostic requirements.

Ferritin Testing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Ferritin Testing industry?

• In March 2025, Connect Biopharma announced the publication of positive Phase 2 data for rademikibart, an anti–IL-4Rα monoclonal antibody, which showed significant improvements in lung function and reductions in asthma exacerbations in patients with moderate-to-severe, Type 2–driven asthma. The treatment demonstrated a favorable safety profile, with no cases of hypereosinophilia observed. Following an End-of-Phase 2 meeting, the FDA agreed to advance rademikibart into Phase 3 trials.
• In May 2024, GSK announced that its experimental biologic depemokimab for eosinophilic asthma met primary endpoints in a late-stage trial, significantly reducing asthma attacks. The ultra-long-acting treatment, with a potential six-month dosing interval, is projected to reach peak sales of up to £3 billion.

Report Coverage:

By Type

• Reagents & assay kits
• Instruments
• Consumables
• Software & middleware
• Services

By Sample Type

• Serum
• Plasma
• Whole blood
• Dried blood spot

By Technology

• Chemiluminescent immunoassay
• Enzyme-linked immunoassay (ELISA)
• Immunoturbidimetry
• Nephelometry
• Immunofluorescence assay
• Lateral flow rapid tests
• Others

By Analyte Scope

• Single-analyte ferritin
• Iron studies panel
• Inflammation-adjusted panels
• Extended anemia workup bundles

By End User

• Hospital laboratories
• Independent laboratories
• Diagnostic center labs
• Physician office labs (POLs) & clinics
• Dialysis centers
• Oncology centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Thermo Fisher Scientific Inc.
• bioMérieux SA
• Siemens Healthineers AG
• Abbott Laboratories
• Roche Diagnostics
• HORIBA Ltd.
• Randox Laboratories Ltd.
• DiaSys Diagnostic Systems
• Danaher Corporation
• Sysmex Corporation
• Abnova Corporation
• Aviva Systems Biology Corporation
• Eurolyser Diagnostica GmbH
• Monobind Inc.
• Sekisui Diagnostics LLC

Frequently Asked Questions (FAQs)